Galectin-3 (Gal-3), a ubiquitously expressed gene involved in many cellular processes, has been recently recognized as a factor related to endometrial receptivity. However, the precise biological function of Gal-3 in the endometrium and its regulation is still unclear. In this study, we detected the antiapoptotic role of Gal-3 in endometrial cells and the expression of Gal-3 regulated by estrogen and progesterone. We found that expression of Gal-3 increased when exposed to the apoptosis inducer staurosporine. Gal-3-silenced endometrial cells were more sensitive to the apoptosis inducer. Estradiol (E2) and progesterone (P4) up-regulated Gal-3 expression, which in turn decreased the apoptotic rate of endometrial cells. Our results strongly suggested that hormonal activation of Gal-3 by E2 and P4 is involved in inhibiting endometrial cell apoptosis, playing key roles in embryo implantation. apoptosis, endometrium, estrogen, Galectin-3, progesterone
INTRODUCTION
The mammalian uterus changes dramatically to prepare for blastocyst implantation and initiation of pregnancy. There is only a small window of time during the menstrual cycle in which the endometrium is receptive to implantation [1] . To become receptive to implantation, dynamic changes occur in the endometrium, including proliferation and apoptosis of endometrial cells [2] [3] [4] . Apoptosis in these cells helps to coordinate the invasion of trophoblastic cells into maternal tissue. This complex apoptotic process in the maternal-fetal interface requires the involvement of a lot of key factors whose expression levels are control by subtle changes in hormone levels.
Galectin-3 (Gal-3) is a unique b-galactoside-binding protein that contains one carbohydrate recognition domain. Gal-3 is expressed in many cell types including endometrial cells and trophoblasts [5] [6] [7] [8] [9] . Expression of Gal-3 can be detected in the cell nucleus and cytoplasm, on the cell surface, and in the extracellular environment [10] . Gal-3 is involved in many cellular processes such as apoptosis and proliferation, as demonstrated by studies of its expression in tumors [11] [12] [13] [14] . Recent reports have shown that Gal-3 is related to endometrium receptivity due to its expression at the time of embryo implantation [15] [16] [17] [18] and its absence in nondecidualized endometrium. Our group found that Gal-3 involved in adhesion and proliferation of endometrial cells [19] and extracellular Gal-3 secreted by trophoblastic Gal-3 induced apoptosis of endometrial epithelial cells [9, 20] . However, there is no report about the apoptotic effect of intracellular Gal-3 in endometrial cells, as Gal-3 was located mainly in cytoplasm and apoptosis is a crucial step for receptive endometrium.
Hormonal regulation of proteins related to the formation of receptive endometrium is the central step in the process of pregnancy [21] [22] [23] [24] . During the peri-implantation stage, proliferation of endometrial cells and apoptosis of epithelial cells are triggered mainly by hormones, which induce changes in expression through autocrine, juxtacrine, and paracrine pathways to form and sustain ''endometrium receptivity.'' Specifically, estrogen and progesterone secretion stimulates the expression of key molecules necessary for the endometrium to enter the implantation window. Thus, we investigated the regulation of Gal-3 expression by varying levels of estrogen and progesterone. Given the fact that estrogen and progesterone trigger proliferation and apoptosis of endometrial cells at the time of embryonic implantation, we investigated whether Gal-3 was one of the downstream genes whose regulation by estrogen and progesterone induced its involvment in biological changes in endometrial cells.
We used RL95-2 cells (a well-differentiated human endometrial epithelium-derived cell line) as the model for endometrial epithelial cells. RL95-2 cells have been proven to be responsive to steroid hormones [25, 26] and have been widely used as the model for embryonic implantation to mimic the in vivo situation of the implantation site [27] [28] [29] [30] . Furthermore, various integrins (a6, b1, b4, and b6), the natural receptors for Gal-3, have been found distributed on the plasma membrane of RL95-2 cells [31, 32] . For these reasons, we chose this cell line for our investigation of the regulation of Gal-3 expression and the roles it plays in the cross-talk between embryo and endometrium.
MATERIALS AND METHODS

Cell Culture
Epithelial cell line RL95-2 from human endometrium (CRL1671 [33] CA) containing 10% fetal bovine serum (FBS; Gibco), 2 mM/L-glutamine (Sigma-Aldrich, St. Louis, MO), 10 mM Hepes (Sigma), 0.5 lg/ml insulin (Sigma), 100 IU/ml penicillin (Gibco), and 100 lg/ml streptomycin (Gibco) at 378C in a humid atmosphere with 5% CO 2 . Culture medium was changed every 2-3 days.
siRNA Transfection Assay
Approximately 1 3 10 6 RL95-2 cells in 1 ml of medium were plated on a 6-well plate and grown for 24 h in medium containing 10% FBS without antibiotics. All transfection reagents (Lipofectamine 2000, opti-MEM reduced serum medium) and short interfering RNAs (siRNAs; Gal-3 stealth siRNA, Stealth RNAi Negative) were purchased from Invitrogen. Gal-3 stealth siRNA templates (GALIG HSS 149595; Invitrogen) were 5 0 -CUU UCU UCC CAA AUC UGC UGC UGG A-3 0 ; and 5 0 -UCC AGCAGC AGA UUU GGG AAG AAA G-3.
0 The Gal-3 siRNA treatment group was transfected with 100 nM Gal-3 siRNA, and the negative siRNA control group was transfected with 100 nM negative siRNA. The mock group was transfected using Lipofectamine 2000 without siRNAs following instructions from the manufacturer. The procedure involved adding 2.5 ml of siRNA or 1.5 ml of Lipofectamine 2000 to 50 ml of opti-MEM-reduced serum medium (in separate tubes) and incubating it for 5 min at room temperature. The mixtures were then combined and incubated at room temperature for an additional 15 min and then added to the wells. Cells were harvested 72 h later for verification of Gal-3 protein expression.
Real-Time-PCR Analysis
RNA was extracted using Trizol reagent (Invitrogen), and the purity of RNA was determined by the ratio of absorbance (A) readings at 260 nm and 280 nm (A 260 /A 280 ) by UV spectrophotometer. Total RNA (1 lg) was reverse transcribed using a PrimeScript RT reagent kit (Takara, Dalian, China). Reverse transcription-PCR was performed prior to quantitative real-time PCR. mRNA levels were determined by real-time PCR using SYBR Premix ExTaq (TaKaRa) with Applied Biosystems 7000 system SDS software, as previously described [19] . GAPDH was used as an endogenous control to normalize for differences in the amount of total RNA in each sample. Primer sequences and sizes of the amplified fragments for Gal-3 (93 bp) were 
Western Blotting
Protein samples were extracted from cells using eukaryotic cell lysis buffer (Biocolor, Shanghai, China). The concentration of protein was measured by using the bicinchoninic acid method. Samples were run in SDS-PAGE and then transferred to nitrocellulose membranes and immunoblotted overnight at 48C with primary antibodies, monoclonal mouse anti-human Gal-3 (mab 1154; R&D Systems, Inc., Minneapolis, MN) antibody (1:2500 dilution), and monoclonal mouse anti-human GAPDH (Kangchen, Shanghai, China) antibody (1:5000 dilution). Then, the samples were incubated with horseradish peroxidase-conjugated secondary antibodies (Kangchen). Reactions were detected by enhanced chemiluminescence assay. GAPDH was used as an endogenous control to normalize for differences.
Cell Viability Analysis
RL95-2 cells were seeded in 96-well plates, in 100 ll of growth medium. Following an overnight attachment period, the cells were exposed to various concentrations of staurosporine (10 and 100 ng/ml and 1 lg/ml) for 24 h. After this period, 20 ll of a 5 mg/ml stock solution of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) was added to each well. Four hours later, 150 ll of DMSO was added to dissolve the dark blue formazan crystals that formed in the living cells. The absorbance of each well at 490 nm (A 490 ) was determined using a Bio-Rad model 450 microplate reader (Bio-Rad Laboratories, Richmond, CA). The background A 490 of the wells that did not contain cells was subtracted before the percentage of viable cells was calculated ([A 490 of 17-AAG-treated sample/A 490 untreated cells] 3 100%).
Flow Cytometry Analysis of Cell Apoptosis
RL95-2 cells were harvested by trypsinization and staining using an Alexa Fluor 488 annexin V/propidium iodide (PI) detection kit (Invitrogen) according to the manufacturer's protocol. Cells were washed in cold PBS and resuspended in 100 of ll 13 annexin-binding buffer. Then, 5 ll of annexin V-fluorescein isothiocyanate (FITC) and 1.5 ll of the 100 lg/ml PI working solution were mixed with the cells and incubated in the dark at room temperature for 15 min. Early apoptotic cells labeled with annexin V-FITC but not PI. Experiments were performed in duplicate and repeated three times.
Staining with Acridine Orange
Acridine orange/ethidium bromide staining can discriminate between live, apoptotic, and necrotic cells. To stain the cells, 25 ll of the cell suspension (10 3 cells) was incubated with 1 ll of 1 part acridine orange (100 lg/ml):1 part ethidium bromide (100 lg/ml). The slides were observed under a fluorescence microscope. Images were analyzed, and cells were counted using Image Pro Plus software. The number of live cells, apoptotic cells, and necrotic cells in the control and treated groups were counted manually.
FIG. 1. Cell apoptosis analysis. A)
Cell viability analysis by MTT. RL95-2 cells were treated with staurosporine (0.01, 0.1, and 1 lg/ml) for 24 h. Cell viability was significantly reduced by 1 lg/ml staurosporine. RL95-2 cells were treated with staurosporine (1lg/ml) for 0, 6, 12, and 24 h. B) Cells were harvested and stained with acridine orange/ethidium bromide dyes, and images were captured by fluorescence microscopy. The images of staurosporine treatment over longer times show more orange-colored cells with fragmentation than control cells. Original magnification 3400. C) Early apoptotic cells were labeled with annexin V-FITC but not PI. The apoptotic rate was recorded by flow cytometry (*P , 0.05) YANG ET AL.
Hormone Stimulation Protocol
For the hormone stimulation test, 5 3 10 5 cells in 1 ml of medium were plated on a 6-well plate and grown for 24 h in normal medium containing 10% FBS without antibiotics. Then, the medium was rum-free and phenol red-free culture medium for 24 h to prepare it for the stimulation experiment. Stimulation was performed using various concentrations of 17b-estradiol alone (E2; at 0 and 10 À10 to 10 À8 M; Sigma) and various concentrations of progesterone (P4; at 0 and 10 À9 to 10 À7 M; Sigma) and with E2 combined with P4 (10 À8 M E2 with 10 
Statistics
Data were expressed as means 6 SEM. One-way ANOVA was performed and least significant difference was applied for post hoc testing using SPSS version 15.0 software, with a P value of ,0.05 considered statistically significant.
RESULTS
Increased Apoptosis in Gal-3-Silenced Endometrial Cells Induced by Staurosporine
Although apoptosis induction by staurosporine has been reported in cancer cells [34] , no evidence has shown the proapoptotic effect of staurosporine in endometrial cells. In our study, we treated endometrial RL95-2 cells with staurosporine, and our results confirmed the proapoptotic effect of staurosporine. MTT results showed that 80.33% 6 4.86%, 79.76% 6 5.27%, and 41.90% 6 2.22% of RL95-2 cells survived after exposure to 10 ng/ml, 100 ng/ml, and 1lg/ml staurosporine for 24 h, respectively (Fig. 1A) . Our results suggested that 1 lg/ml staurosporine was capable of affecting cell viability effectively. Some papers have reported that 1 lg/ml staurosporine effectively induced apoptosis in cancer cells [34] . Thus, we used 1 lg/ml staurosporine to induce apoptosis in RL85-2 cells. As shown in Figure 1 , B and C, the apoptosis rates of RL95-2 were approximately 43.3%, 52.7%, and 73.3% with cells incubated with 1 lg/ml staurosporine for 6, 12, and 24 h, respectively. To accurately measure differences in apoptosis rates between siRNA-treated and nontreated cells, we chose 12-h treatments with staurosporine in subsequent experiments. To examine the role of Gal-3 in staurosporine-induced apoptosis, mRNA and protein levels were qualified while cells were exposed to staurosporine for 6, 12, and 24 h. As shown in Figure 2 , the expression of Gal-3 increased in a time-dependent manner and arrived at its maximum at 24 h after exposure to staurosporine. To further investigate the effect of Gal-3 in staurosporine-induced apoptosis, we knocked down the expression of Gal-3 as published previous by our group [19] and confirmed the down-regulated expression of Gal-3 by Western blot analysis (Fig. 3A) . Then, the cells were exposed to staurosporine for 12 h. The cells pretreated with the Gal-3 FIG. 2. Gal-3 expression when RL95-2 cells were exposed to staurosporine. RL95-2 cells were treated with staurosporine (1 lg/ml) for 0, 6, 12, and 24 h, and mRNA levels (A) and protein levels (B) of Gal-3 were detected by real-time PCR and Western blotting. Gal-3 expression in RL95-2 cells increased according to the length of time exposed to staurosporine (*P , 0.05)
FIG. 3. Knocked-down Gal-3 increased apoptosis of RL95-2 cells. A)
Western blot analysis of Gal-3 siRNA transfection. Gal-3 protein expression was reduced significantly after 72 h of siRNA transfection (*P , 0.05). S represents the Gal-3 siRNA-transfected group; N represents the negative siRNA transfected cells (negative control group); M represents cells that were incubated only with Lipofectamine 2000 (mock group). B) At 24 h after RL95-2 cells were transfected with siRNA, staurosporine (1 lg/ml) was added to culture medium for 12 h, and apoptosis was analyzed by flow cytometery (*P , 0.05).
ANTIAPOPTOTIC EFFECT OF INTRACELLULAR GAL-3
siRNA suggested an increased apoptosis rate (68.5%) compared with the cells pretreated with negative siRNA (52.7%), which indicated that Gal-3 had an antiapoptotic effect in staurosporine-induced apoptosis (Fig. 3B) .
Up-Regulated Expression of Gal-3 by Hormones in RL95-2 Cells
Knowing the antiapoptosis effect of Gal-3 in RL95-2 cells, it is interesting to find the factor that regulates the expression of Gal-3. E2 and P4 are hormones that are important for regulating some key molecules in endometrium at the time of embryonic implantation. Therefore, we investigated the regulation of Gal-3 by E2 and P4. Compared with control, the expression of Gal-3 mRNA in RL95-2 cells increased significantly after treatment with E2 for 24 h, 48 h, and 72 h (Fig. 4A) . The up-regulation of Gal-3 in response to E2 was further validated at protein levels by Western blotting (Fig.  4B) . We treated cells with E2 (10 À8 ) for 24, 48, and 72 h. As shown in Figure 4 , C and D, the expression of Gal-3 mRNAs and proteins increased at all time points compared with that in the control.
We found that the expression of Gal-3 in RL95-2 cells was also increased by P4 at all dosage (Fig. 5) . We treated cells with P4 (10 À7 ) for 24, 48, and 72 h, and the expression of Gal-3 increased at all time points, as shown by real time-PCR and Western blotting. Treating the cells with a combination of E2 (10 À8 ) and P4 (10 À7 ) resulted in an increase in expression of Gal-3 compared with treatments by E2 or P4 alone (Fig. 6) . Our results indicated that Gal-3 was regulated by E2 and P4 in endometrial cells.
Decreased Apoptosis Due To Increased Gal-3 Expression in E2-and P4-Treated RL95-2 Cells E2 and P4 are important factors in the regulation of proliferation and apoptosis of endometrial cells at the time of embryonic implantation; thus, we asked whether Gal-3 is one of the downstream genes regulated by E2 and P4, to be involved in apoptosis of endometrial cells. RL95-2 cells were first treated with Gal-3 siRNA, and in 36 h, estrogen/ progesterone was added to the medium. After another 24 h, staurosporine was added, and finally the apoptosis rate of cells was measured in 12 h (Fig. 7) . In negative siRNA group, E2 or P4 treatment showed a decreased apoptosis rate in RL95-2 cells. However, in the Gal-3 siRNA group, although the apoptosis rate was decreased by E2 or P4, it was still higher than that of E2 or P4 treatment in the siRNA-negative group.
DISCUSSION
Our previous studies showed that Gal-3 significantly increased in the mid-secretory phase of the menstrual cycle [35] , which was the key time for the formation of receptive endometrium. However, the effect of intracellular Gal-3 on apoptosis in endometrial cells is still unknown. Evidence has YANG ET AL. accumulated to support the notion that the process of embryo implantation shares many similarities with the invasion and metastasis of cancerous tumors and that intracellular Gal-3 has an antiapoptosis effect in tumor cells. We hypothesized that Gal-3 may also function as an antiapoptotic factor in endometrial cells, to be involved in the formation of receptive endometrium.
We verified the apoptotic effect of staurosporine in endometrial cells. We found that Gal-3 expression increased with exposure to staurosporine, which suggested that Gal-3 expression in endometrial cells was increased by the presence of apoptosis inducers. Gal-3 expression might be increased to resist the proapoptotic effect of staurosporine. To further examine the antiapoptotic effect of Gal-3 in endometrial cells, we knocked down the expression of Gal-3 in RL95-2 cell lines by using the siRNA technique. We found that Gal-3-silenced RL95-2 cells were more sensitive to staurosporine-induced apoptosis, which was similar to the antiapoptotic effect in tumor cells. Our results indicated that increased Gal-3 expression at the time of implantation may have an antiapoptotic effect on endometrial cells. It has been shown previously that Gal-3 could act as an antiapoptotic factor during tumor proliferation and metastasis. It contains an NWGR antideath motif of the Bcl-2 family and presumably inhibits cell apoptosis of tumor cells by sharing a common pathway with Bcl-2 [10] . The detailed antiapoptotic mechanism of Gal-3 in endometrial cells needs further investigation.
During embryonic implantation, E2 promotes endometrial epithelial proliferation and inhibits apoptosis. Also, circulating concentrations of P4 are maintained at high levels during implantation in pregnant mice [36] and rats [37] . Levels of P4 mRNA and protein expression also remain high in uterine tissues [38] , indicating P4's possible role in inhibiting uterine cell death. Our previous study indicated that Gal-3 significantly increased in the mid-secretory phase of the menstrual cycle [35] , so we wondered whether Gal-3 expression was regulated by estrogen and progesterone. Our results showed that E2 and/ or P4 at all dosage increased Gal-3 expression in endometrial cells. Furthermore, E2 and P4 increased Gal-3 expression at all time points, suggesting that they are involved in the regulation of Gal-3 expression. However, we showed no evidence for direct regulation in this work. In fact, it is likely that Gal-3 is indirectly regulated by estrogen and progesterone, for we do not find estrogen receptor (ER) and progesterone receptor (PR) binding motifs in its promoter region.
E2 and P4 are key regulators involved in proliferation and apoptosis of endometrial cells. We hypothesized that Gal-3 functions as an antiapoptotic factor under the regulation of E2 and P4. In Figure 7 , we show that E2/P4 can protect RL95-2 cells from apoptosis (Fig. 7, left) . The antiapoptotic effects of E2/P4 were abolished if Gal-3 was knocked down by siRNA (Fig. 7, right) . This indicates that their antiapoptotic function is mediated mainly by up-regulation of Gal-3. Interestingly, a decrease in apoptotic rate was also observed when the cells were treated with Gal-3 siRNAs without adding estrogen/ progesterone. This was caused by the fact that Gal-3 was expressed at a low level even without estrogen/progesterone stimulation. Down-regulation of the basal level of Gal-3 can also lead to an enhanced apoptotic rate in RL95-2 cell. Taken together, the antiapoptotic role of Gal-3 is revealed at the basal level (without E2/P4 treatment) and after hormone stimulation (with E2/P4 treatment). This result is consistent with that of other reports showing that progesterone prevents cell death [39, 40] . À7 M P4 for 24 h; or with 10 À7 M P4, and Gal-3 expression was analyzed at 0, 24, 48, and 72 h after P4 treatment. Total protein and RNA were extracted, and Gal-3 expression was analyzed by real-time PCR and Western blotting. Cells treated with vehicle (0 M P4) served as control. GAPDH was used as an endogenous control to normalize for differences. The graph demonstrates the Gal3/GAPDH as relative value for10 
ANTIAPOPTOTIC EFFECT OF INTRACELLULAR GAL-3
In conclusion, our study suggested that intracellular Gal-3 has an antiapoptotic effect in endometrial cells and that E2 and P4 may prevent endometrial cell apoptosis through upregulating Gal-3 expression. However, further investigation is needed to determine whether Gal-3 is directly or indirectly regulated by hormones.
FIG. 7. E2 and P4 prevented cell apoptosis partly through Gal-3. After RL95-2 cells were incubated with Gal-3 siRNA or not (Negative siRNA) for 48 h, E2 (10 À8 M) or P4 (10 À8 M) was added to the culture medium for 24 h. Then, the cells were treated with staurosporine (1 lg/ml) for 12 h. The apoptotic rate was then analyzed. Control represents cells that were not treated with E2 or P4. E2 represents RL95-2 cells treated only with E2 and without P4. P4 represents RL95-2 cells treated only with P4 and without E2 (*P , 0.05). À8 M only (E2), P4 10 À7 M only (P4), and E2 10 8 M plus P410 À8 M (EP), or vehicle control (Control). Total protein and RNA were extracted, and Gal-3 expression was analyzed by real-time PCR (A) and Western blotting (B). Cells treated with vehicle served as control. GAPDH was used as an endogenous control to normalize for differences (*P , 0.05).
